EGFR and nasopharyngeal carcinoma: Cetuximab, an anti-EGFR monoclonal antibody, has demonstrated marginal activity in patients with pretreated r/m NPC, achieving an ORR of 11.7%, median PFS of 81 days, and median OS of 233 days in combination with carboplatin in a phase 2 study [53].